Previous 10 |
ADMA Biologics (NASDAQ: ADMA ) has responded to the July 2016 Complete Response Letter (“CRL”) and resubmitted its Biologics License Application (“BLA”) for RI-002 to the FDA on September 28, 2018. More news on: ADMA Biologics Inc, Healthcare stocks news, Stoc...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...